Amazing what a CR can do to get a bit of attention from...

Amazing what a CR can do to get a bit of attention from Investors, so close to inflection points @ Eqz. Many a time in biotechs, it doesn’t do much after the pump, but this is a bit different this time; with Orphan Status & only one trial required on a Ph3 for that in FSGS if Ph2 successful (you have to add that even though they have been to the FDA recently for IND on a Ph3), & other indications that can be applied for with market exclusivity on top of patents (DKD).

Very attractive to Big Pharma, both for safety & efficacy in a clinically unmet need. Both indications, because our numbers are better in Ph2A from diabetes & no SAEs, unlike Invokana. (PIQ have a collaboration with for PromarkerD, Janssen, J&J), the first drug to be approved by the FDA in the last 20yrs for DKD, & DXB have a licensing agreement on PromarkerD too.

The drug is already speaking for efficacy anyway with Ph2A patients remaining on it from SAS (Special Access Scheme with TGA).

Feel like I’m repeating myself, but there are a few important ‘differences’ here in this stock for holders of Ph2 biotechs, IP & status with the FDA. A very professional & forward thinking company. Do your own DD people. There is no need to say more.

GLTAH